Galectin Therapeutics (GALT) Stock
Biotech company developing galectin inhibitors for liver and cancer. Here's the price, business snapshot, and what's worth knowing about Galectin Therapeutics in August 2026.
Galectin Therapeutics Inc (GALT) is a clinical-stage biotechnology company focused on therapies that inhibit galectin proteins, particularly galectin-3, which are implicated in fibrosis and certain cancers. Its lead candidate, belapectin (GR-MD-02), has been evaluated for non-alcoholic steatohepatitis (NASH) with cirrhosis and portal hypertension and has been explored in oncology combinations. The company has no approved products and its value is closely tied to clinical trial outcomes, regulatory decisions, partnership activity and access to financing. With a market capitalisation near $340 million, GALT is a small-cap, high-volatility stock: investors should expect sharp moves around trial readouts and news. Key risks include clinical failure, regulatory setbacks and dilution from future funding rounds. The company holds intellectual property around galectin inhibitors and has sought collaborations to advance programmes. This summary is educational only and not personal financial advice; investors should assess suitability for their own circumstances and tolerance for speculative biotech risk.
About This Stock
GALECTIN THERAPEUTICS INC
GALT
Current Price
$3.67
Potential 12 Month Profit
220.70%
Sector
N/A
Industry
N/A
Ticker
GALT
Market Cap
$370.12M
Potential 12 Month Profit
220.70%
Sector
N/A
Industry
N/A
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Galectin Therapeutics stock, anticipating its price could rise significantly.
Financial Health
Galectin Therapeutics is generating positive cash flow, but its overall financial performance is average.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Trial Readouts Matter
Company value often moves on clinical results and regulatory milestones; meaningful readouts can shift sentiment, though outcomes are uncertain.
Targeting Fibrosis
Galectin‑3 inhibition is a novel therapeutic approach to fibrosis and cirrhosis with scientific rationale, but clinical proof of benefit remains necessary.
Funding & Partnerships
As a small‑cap biotech, progress depends on financing and collaborations; watch for potential dilution and partnership announcements.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.